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Splicing of pre-mRNA requires multiple components that can
form a stable spliceosome, and a number of factors that can stabi-
lize the interaction of the spliceosome with the pre-mRNA mole-
cule. Several nuclear ribonucleoprotein (RNP)-binding proteins
have been identified, that are both essential for splicing and can
influence splice-site selection (Spritz et al, 1987; Kohtz et al,
1994). Some of the best characterized factors belong to a large
family of proteins that contain a serine/arginine-rich domain, thus
named SR proteins (SR). SR proteins can complement splicing-
inactive S100 fractions and alter splice-site selection in alterna-
tively spliced pre-mRNAs (Zahler et al, 1993). Moreover, there is
evidence that SR protein splicing factors are involved in cancer
pathobiology through their effect on alternative processing deci-
sions (Gobert et al, 1996; Stickeler et al, 1999). 
In rat and yeast, the SR proteins have been characterized as part
of a large complex which is directly associated with the C-terminal
domain (CTD) of the large subunit of RNA polymerase II (CTD)
(Yuryev et al, 1996), Detailed analyses of its interaction with the
SR proteins suggests that the CTD domain, in complex with the SR
proteins, may be involved in the early post-initiation events taking
place during mRNA synthesis, including splicing. Yuryev et al
employed the yeast 2-hybrid system, to identify proteins that
interact with the CTD and cloned 4 distinct rat cDNAs that encode
for high molecular mass SR proteins (Yuryev et al, 1996). The
predicted rat SR proteins, namely rA1, rA4, rA8 and rA9 range in
size from 120 to 140 kDa. 
In humans, 9 distinct SR-encoding genes have been identified
and characterized to date. These include the SF2/ASF and its
alternatively spliced isoforms ASF-2 and ASF-3 (Ge et al, 1991),
SC35 (Fu and Maniatis, 1992; Vellard et al, 1992), SRp20 (Kim
et al, 1992), SRp30 (Screaton et al, 1995) SRp40 (Meier, 1996),
SRp55 (Screaton et al, 1995), SRp75 (Zahler et al, 1993), 9G8
(Cavaloc et al, 1994) and SRrp129/CASP11 (Tanner et al, 1997).
In addition, a set of high molecular weight proteins that cross-
react with SR-specific monoclonal antibodies, has also been
identified in human cell lines (Blencowe et al, 1994). However,
only one gene encoding for a high molecular mass SR protein,
SRrp129/CASP11, has been identified (Tanner et al, 1997). The
SRrp129/CASP11 protein was shown to contain both an SR
domain and CTD-binding domain. Similar to the rat SR proteins,
the SRrp129/CASP11 protein was also implicated in RNA
splicing (Tanner et al, 1997). 
In this study we report the identification of a novel human gene,
encoding for high molecular mass SR protein, distinct from the
SRrp129/CASP11, that appears to be the human homologue of the
rat A1 gene. The new gene was named SR-A1, and was identified
by positional cloning. The human SR-A1 gene was mapped to
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Summary By using the positional cloning gene approach, we were able to identify a novel gene encoding for a serine/arginine-rich protein, which
appears to be the human homologue of the rat A1 gene. We named this new gene SR-A1. Members of the SR family of proteins have been
shown to interact with the C-terminal domain (CTD) of the large subunit of RNA polymerase II and participate in pre-mRNA splicing. We have
localized the SR-A1 gene between the known genes IRF3 and RRAS on chromosome 19q13.3. The novel gene spans 16.7 kb of genomic
sequence and it is formed of 11 exons and 10 intervening introns. The SR-A1 protein is composed of 1312 amino acids, with a molecular mass
of 139.3 kDa and a theoretical isoelectric point of 9.31. The SR-A1 protein contains an SR-rich domain as well as a CTD-binding domain present
only in a subset of SR-proteins. Through interactions with the pre-mRNA and the CTD domain of the Polymerase II, SR proteins have been
shown to regulate alternative splicing. The SR-A1 gene is expressed in all tissues tested, with highest levels found in fetal brain and fetal liver.
Our data suggest that this gene is overexpressed in a subset of ovarian cancers which are clinically more aggressive. Studies with the steroid
hormone receptor-positive breast and prostate carcinoma cell lines ZR-75-1, BT-474 and LNCaP, respectively, suggest that SR-A1 is
constitutively expressed. Furthermore, the mRNA of the SR-A1 gene in these cell lines appears to increase by estrogens, androgens and
glucocorticoids, and to a lesser extend by progestins. © 2001 Cancer Research Campaign http://www.bjcancer.com
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human chromosome 19 (19q13.3) and is localized between the
known genes IRF3 and RRAS. The predicted protein is highly
homologous to the rat A1 SR protein, and contains both signature
domains present in the rat and human high molecular weight SR
proteins, namely the CTD and SR. Levels of the SR-A1 transcripts
were found to be increased in the breast and prostate carcinoma
cell lines ZR-75-1, BT-474 and LNCaP, respectively, in response
to hormone stimulation. In a subset of ovarian tumours tested, we
found that higher expression of the SR-A1 gene is associated with
clinically more aggressive disease. 
MATERIALS AND METHODS 
Gene identification and mapping 
In our search for new SR-encoding genes involved in the process
of pre-mRNA splicing, blast search was performed for different
CTD-binding conserved motifs, using the TBLASTN program
against the unfinished High Throughput Genomic Sequences data-
base (htgs). A potential CTD-binding domain was identified in the
BAC clone BC42053 sequenced by the Department of Energy’s
Joint Genome Institute. Genomic sequences from this clone and
the particle overlapped BC 878087, were in the form of 167
contigs of different lengths. Restriction enzyme sites of the
sequences were determined using the ‘WebCutter 2’ computer
program. The chromosome 19 EcoR1 restriction map (Ashworth
et al, 1995), information from BAC and PAC end sequences, and
long PCR strategies and sequencing were used to construct a
contiguous area of approximately 50 kb in length, of the genomic
area of interest. The published sequences of the RRAS and IRF3
genes, were used to identify the relative positions of these genes
on the contiguous map using the BLAST 2 algorithm (Altschul
et al, 1997). Bioinformatic approaches were used to predict the
presence of putative new genes within this genomic region
(Murakami and Takagi, 1998; Scorilas et al, 2000, 2001; Yousef
et al, 2000a, b, c, 2001). 
Expressed sequence tag (EST) searching 
The predicted exons of the putative new gene were subjected to
homology search using the BLASTN algorithm (Altschul et al,
1997) against the human EST database (dbEST). Clones with >95%
identity were obtained from the I.M.A.G.E. consortium (Lennon et
al, 1996) through Research Genetics Inc, Huntsville, AL and from
the Institute for Genomic Research (TIGR), Rockville, MD. Clones
were propagated and purified and then sequenced from both direc-
tions with an automated sequencer, using insert-flanking vector
primers. All clones tested are shown in Table 1. 
Protein homology searching 
Putative exons of the newly identified gene were first translated to
the corresponding amino acid sequences. BLAST homology
searching for the proteins encoded by the exons were performed
using the BLASTP algorithm and the GenBank databases
(Altschul et al, 1997). 
Structure analysis of the SR-A1 protein 
Multiple alignment was performed using the clustal X multiple
alignment program (Aiyar, 2000). Phylogenetic studies were
performed using the Phylip software package (Retief, 2000).
Distance matrix analysis was performed using the ‘Neighbor-
Joining/UPGMA’ program and parsimony analysis was done using
the ‘Protpars’ program (Takezaki, 1998). Hydrophobicity study
was performed using the Baylor College of Medicine search
launcher program. Signal peptide and transmembrane regions
prediction studies were performed using the SignalP (Nielsen et al,
1999) and Tmpred (Hofmann and Stoffel, 1992) software. Protein
structure analysis was performed by SAPS program (Brendel et al,
1992). Sequence analysis tools were utilized to detect the presence
of possible sites of post-translational modification on the SR-A1
protein. We used the analysis program PROSITE (Bairoch et al,
1997) and NetOGlyc 2.0 (Hansen et al, 1998) to detect N- and O-
glycosylation, as well as the presence of kinase phosphorylation
motifs. 
Cell lines and hormonal stimulation 
The breast cancer cell lines ZR-75-1 and BT-474 as well as the
prostate cancer cell line LNCaP were purchased from the
American Type Culture Collection, Rockville, MD. Cells were
cultured in RPMI media (Gibco BRL, Gaithersburg, MD)
supplemented with glutamine (200 nmol l–1), bovine insulin
(10 mg l–1), fetal bovine serum (10%), antibiotics and antimy-
cotics, in plastic flasks, to near confluency. The cells were then
aliquoted into 24-well tissue culture plates and cultured to 50%
confluency. The culture media were changed to phenol red-free
media containing 10% charcoal-stripped fetal bovine serum 24
hours prior to stimulation. Hormonal stimulation was performed
by the addition of various steroid hormones, dissolved in 100%
ethanol, to the culture media at a final concentration of 10–8M.
Cells stimulated with 100% ethanol were included as negative
controls. The cells were cultured for 24 hours before mRNA
extraction. 
Tissue expression 
Total RNA isolated from 28 different human tissues was
purchased from Clontech, Palo Alto, CA. We prepared cDNA as
described below, and used it for PCR reactions. Tissue cDNAs
Table 1 EST clones with >95% identity to exons of the SR-A1 gene 
GenBank  Tissue I.M.A.GE. ID Homologous exons 
accession no.
AW405880 Testis 3059116 2–7 
T85786 Fetal liver 112665 2–4 
AI806513 Fetal lung 2350047 4,5 
D30881 Fetal lung – 7 
R88505 Brain 166268 9,10 
R90751 Brain 167214 9 
R88967 Brain 167004 9–11 
AI123319 Fetal heart 1689976 10 
AI688286 Colon 2325658 10,11 
AW473167 Uterus 2750431 10 
AA847768 Colon tumour 1419781 11 
AA568253 Colon 1057491 11 
AW298066* Lung 2732727 11 
AW296699* Brain 2730645 11 
*Contains a Poly(A) tail. were amplified using the primers F7 and R9, described in Table 2.
PCR products were gel-purified and sequenced. 
Ovarian cancer and non-cancer tissues 
Included in this study were specimens from 40 cancer and 5 non-
cancer ovarian tissues. Patients were undergoing surgical treat-
ment for primary ovarian carcinoma at the Department of
Gynecology and Gynecologic Oncology Unit at the University of
Turin, Turin, Italy, during the period from January 1996 to
December 1998. This study had been approved by the Ethics and
Research Committee at the institutional Review Board of the
University of Turin. Normal ovaries were removed from patients
who underwent surgery for benign non-ovarian pathology. Patient
age ranged from 33–78 years with a median of 60. All patients had
a histologically confirmed diagnosis and received no treatment
before surgery. Classification followed the World Health
Organization criteria (Serov and Sorbin, 1973). Clinical staging
was performed according to the International Federation of
Gynecology and Obstetrics (FIGO) staging system (Pettersson,
1994). Histologic grading was performed according to the criteria
of Day et al; highly differentiated tumours were grade 1 and undif-
ferentiated tumours grade 3 (Day et al, 1975). Ovarian tissue had
been frozen in liquid nitrogen immediately after surgery. We
prepared cDNA as described below and used it for PCR reactions
with the primers F7 and R9. Tissue cDNAs were amplified at a
1:20 dilution (Kim et al, 2001). 
Reverse transcription polymerase chain reaction 
(RT-PCR) 
Total RNA was extracted from the tissues or cell lines using Trizol
™ reagent (Gibco BRL) following the manufacturer’s instruc-
tions. RNA concentration was determined spectrophotometrically.
2 mg of total RNA was reverse transcribed into first strand cDNA
using the Superscript™ preamplification system (Gibco BRL,
Gaithersburg MD). The final volume was 20 ml. Based on the
combined information obtained from the predicted genomic struc-
ture of the new gene and the EST sequences, 2 gene-specific
primers were designed (F7 and R9; Table 2) and PCR was carried
out in a reaction mixture containing 1 ml of cDNA, 10 mM Tris-
HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 200 mM dNTPs
(deoxynucleoside triphosphates), 150 ng of primers and 2.5 units
of AmpliTaq Gold DNA polymerase (Roche Molecular Systems,
Branchburg, NJ, USA) on a Perkin-Elmer 9600 thermal cycler.
The cycling conditions were a denaturation step at 95°C for 15
minutes, followed by 42 cycles of 94°C for 30 s, 64°C for 1 min
and a final extension at 64°C for 10 min. Equal amounts of PCR
products were electrophoresed on 2% agarose gels and visualized
by ethidium bromide staining. The primers for RT-PCR spanned at
least 2 exons to avoid contamination by genomic DNA. 
Cloning and sequencing of the PCR products 
To verify the identity of the PCR products, they were cloned into
the pCR 2.1-TOPO vector (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions. The inserts were
sequenced from both directions using vector-specific primers, by
an automated DNA sequencer. 
Statistical analysis 
Statistical analysis was performed with SAS software (SAS
Institute, Cary, NC). Ovarian tumour SR-A1 mRNA levels were
qualitatively classified into 2 categories (SR-A1 – low and SR-A1
– high groups). All samples were evaluated for SR-A1 expression
by 2 observers who were unaware of patient outcome.
Associations between SR-A1 status and other qualitative variables
were analysed using the Fisher’s exact test. Because of the small
number of cases, tumour grade was categorized into 2 groups: I
and II–III. The stage of the disease was also categorized into 2
groups: I–II and III–IV. The analysis of differences in SR-A1
status and age or residual tumour size was performed with the
nonparametric Mann–Whitney U test. 
RESULTS 
Cloning of the SR-A1 gene 
Analysis of the constructed contiguous genomic sequences in the
region of chromosome 19q13.3 predicted a putative new gene
formed of 11 exons. To verify the existence of this gene, the puta-
tive exons were subjected to sequence homology search against
the human expressed sequence tag database (dbEST), and 14 EST
clones with > 95% identity were found (Table 1). Some of these
clones were obtained and inserts were sequenced from both direc-
tions. Sequences were compared with the computer-predicted
structure and final selection of the intron/exon splice sites was
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Table 2 Primers used for reverse transcription polymerase chain reaction (RT-PCR) analysis of the SR-A1 and 2 control genes 
Gene Primer name Sequencea Length of PCR 
product 
SR-A1 F1 CTC ACC CCA TTA GCT GTC CC 695 
R6 GAT CTC TGT CCC CGA TTC GG 
F6 CCG AAT CGG GGA CAG AGA TC 2500 
R7 GGA CCA GGA AGT CTC CTC CG 
F7 CGG AGG AGA CTT CCT GGT CC 564 (F7/R9) 
R9 CAT CCC CAG ACT TGA GGG TG 
R11 TCA GGG GTA ATG TTT CAT GA 1302 (F7/R11) 
Actin ACTINS ATC TGG CAC CAC ACC TTC TA 
ACTINAS CGT CAT ACT CCT GCT TGC TG 838 
aAll nucleotide sequences are given in the 5¢®3¢ orientation. Molecular characterization of the SR-A1 gene 193
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done according to the EST sequences. The ESTs matched well
with most of the predicted exons of the gene and 2 of them
possessed a poly(A) tail, confirming the 3¢ end of the mRNA
(Table 1). Moreover, homology search of the exons against the
GenBank database revealed a rat cDNA with 84% identity. This
cDNA encodes for the rat A1 protein, an SR-like protein, and
matches with exons 3–11 our novel human gene (see below). 
To verify the accuracy of the cDNA sequence, PCR reactions were
performed using 3 pairs of primers, specific for various exons of the
gene (F1/R6 extending from exons 1–6; F6/R7 for exons 6–7 and
F7/R11 for exons 7–11; see Table 2) with cDNA isolated from
different human tissues as putative templates. The PCR bands were
cloned and sequenced to further define and confirm the exon/intron
boundaries. The genomic and cDNA sequence of the new gene is
now deposited in GenBank (accession # AF254411). 
Mapping and chromosomal localization of the SR-A1
gene 
Alignment of the SR-A1 gene sequence and the sequences of other
known genes localized within the same area of the chromosome
19q13.3 enabled us to precisely localize these genes and determine
the direction of the transcription, as shown in Figure 1. The SR-A1
gene maps between 2 known genes, namely IRF3 and RRAS and
is transcribed in the opposite direction. The distances between SR-
A1 and IRF3 and RRAS were calculated to be 921 bp and 1821
bp, respectively. We did not predict any other genes between IRF3
or RRAS. 
Characterization of the genomic structure of the SR-A1
gene and its protein product 
The SR-A1 gene, as diagrammatically presented in Figure 2, is
formed of 11 exons and 10 intervening introns, spanning an area of
16 730 bp of genomic sequence on chromosome 19q13.3. The
lengths of the exons are 323, 114, 58, 95, 101, 116, 2838, 83, 219,
129, and 442 bp, respectively. All the intron/exon splice sites and
their flanking sequences are closely related to the consensus splice
sites (-mGTAAGT...CAGm-, where m is any base) (Iida, 1990). 
The protein coding region of the novel gene consists of 3939
nucleotides (including the stop codon), producing a 1312 amino
acid protein, with a predicted molecular mass of 139.3 kDa,
excluding any post-translational modifications, and a theoretical
isoelectric point of 9.31. The translation initiation codon (ATG) at
position 7 of the second exon, was chosen because: (1) The
flanking sequence of this codon (ACCATGG) matches closely
with the Kozak consensus sequence (GCC A/G CCATGG) for
initiation of translation (Kozak, 1991); (2) No other start codon
located within the first 4 exons has the capacity to generate a func-
tional, in-frame mRNA with the remaining exons; (3) Using this
initiation codon, the translated product is similar in length and has
a high degree of homology with other similar proteins (see below).
Thus, we conclude that the first exon is untranslated. The 3¢
terminus of the SR-A1 gene was verified by the presence of a poly
(A) tail in two EST sequences (Table 1). As it is evident from
Figure 2, this gene possesses a 5¢ untranslated region of at least 329
nucleotides, as well as a 3¢ untranslated region of 250 nucleotides. 
To more extensively characterize the predicted structural motifs
of the SR-A1 protein, the SR-A1 protein was aligned with other
members of the SR multi-gene family (Figure 3). SR-A1 is found
to have 78% amino acid identity and 84% similarity with the rat
A1 protein suggesting that the newly identified SR-A1 gene is the
human homologue of the rat A1 gene, reported by Yuryev et al
(Yuryev et al, 1996). The SR-A1 protein showed 24% identity
with the rA9 gene product and 19% identity with the rA4 and rA8.
The SR-A1 protein showed 22% amino acid identity and 33%
similarity with the SRrp129 protein and to a lesser extend (< 20%)
with the low molecular mass SR proteins. As shown in Figures 2
and 3, common SR domains present in the rat A1 and the other SR
proteins were also identified in the SR-A1 predicted protein. The
CTD-binding domain of rat A1, rat A9 and SRrp129 protein was
also present in the SR-A1 protein. Also, two areas with negatively
charged polyglutamic acid (E) stretches which are present in rat
A1 but not in other known SR proteins, were identified (Figures 2,
3). In addition, we identified the presence of an Arg/Asp-rich
motif (RD) in the SR-A1 protein. This motif is also present in a
number of other RNA binding proteins such as the U1-70 K
(Spritz et al, 1987), the RD RNA-binding protein (Surowy et al,
1990) and the 68 kDa human pre-mRNA cleavage factor Im
(Ruegsegger et al, 1998). In addition to the above-described
motifs, this protein is also proline-rich and contains a large number
of PS or SP dinucleotides (n = 39) and a large number of PAP
trinucleotides (n = 16). Overall, the percentage of various amino
acids represented in this protein are S, 13.6%; P, 13.3%; R, 9.8%,
A, 9.3%; E, 8.5% and other amino acids are less than 7%. Other
long stretches of single amino acids (>5) are shown in Figure 2. 
To predict the phylogenetic relatedness of the SR-A1 with other
SR proteins, the amino acid sequences of these genes were aligned
using the ‘Clustal X’ multiple alignment program and a distance
matrix tree was predicted using the Neighbour-joining/UPGMA
method. Figure 4 shows that the SR-A1 is grouped with rat A1
protein, whereas the other known SR-proteins were separated in
other groups. 
Examination of the hydrophobicity profile of the SR-A1 protein
did not reveal regions with long stretches of hydrophobic residues
(Figure 5). This is consistent with findings from a signal sequence
prediction program (Nielsen et al, 1999) which did not predict a
signal sequence. SR-A1 protein is predicted to be a nuclear protein
with no transmembrane region, in agreement with the rat homo-
logue protein. Through the use of sequence analysis tools, we were
able to identify various putative post-translational modification
sites (Table 3). There are numerous potential sites for either O- or
N-glycosylation. Furthermore, several possible sites of phosphory-
lation have been identified for cAMP-dependent protein kinase,
protein kinase C, and casein kinase 2. 
Tissue expression profile of the SR-A1 gene 
RT-PCR was performed on a panel of total RNA preparations
extracted from various tissues. RT-PCR for actin was used as a
positive control. Positive ESTs for SR-A1 were also used as con-
trols. The tissue expression of SR-A1 is summarized in Figure 6.
Figure 1 An approximate 35 kb region of contiguous genomic sequence
around chromosome 19q13.3. Genes are represented by horizontal arrows
denoting the direction of transcription. Gene lengths and distances between
genes are mentioned in base pairs (bp). Figure is not drawn to scale. IRF3,
interferon regulatory factor 3 
6098 bp
IRF3 SR-A1 RRAS
921 bp
19q13.3 Telomere
16 730 bp 1821 bp 4523 bp
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The novel gene is highly expressed in many tissues. Highest levels
of SR-A1 transcripts were detected in the fetal brain and fetal liver
and the lowest in the salivary gland, heart, skin and ovary but virtu-
ally every tissue tested was positive. Cloning and sequencing of the
PCR products ensured specificity. 
Expression of SR-A1 in cancer cell lines 
We used the steroid hormone receptor-positive breast and prostate
carcinoma cell lines ZR-75-1, BT-474 and LNCaP, respectively, as
model systems to evaluate whether SR-A1 is expressed in these
cells. As shown in Figure 7, we could detect expression of SR-A1 in
all 3 cell lines and noticed that the expression was affected by
steroid hormone treatment. Specifically, the mRNA of the SR-A1
gene in ZR-75-1 and LNCaP cell lines appears to increase by oestro-
gens, androgens and glucocorticoids, and to a lesser extend by pro-
gestins. However, since no promoter characterization studies have
been performed, we do not know if the effect of steroid hormones on
SR-A1 transcription is direct or indirect in nature. 
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Figure 2 Schematic representation of the SR-A1 gene and the amino acid sequence of the predicted SR-A1 protein. Exons are shown as boxes and introns
as connecting lines. Arrows show the positions of the start codon, stop codon and polyadenylation signal. Roman numerals indicate intron phases. The intron
phase refers to the location of the intron within the codon; I denotes that the intron occurs after the first nucleotide of the codon, II that the intron occurs after the
second nucleotide, and 0 that the intron occurs between codons. Numbers inside boxes indicate exon lengths and the vertical connecting lines show the intron
lengths (in bp). Figure is not drawn to scale. RS or SR dinucleotides are shown in bold and the CTD-binding domain of the SR-A1 protein is boxed. An Arg/Asp
rich motif (RD) is double-underlined. There are 2 areas with polyglutamic acid (E) stretches which are shown in italics. Other putative motifs (PS, SP, PAP) and
repeated aminoacids, (³ 5) are underlined. The full genomic organization of the gene is reported in GenBank (accession # AF254411) 
Table 4 Relationship between SR-A1 expression (low or high) status and
other clinicopathological variables in ovarian cancer patients 
No. of patients (%) 
Variable Patients SR-A1 low SR-A1 high P valuea
Gradeb
I 5 4 (75.0%) 1 (25.0%) <0.001 
II-III 33 3 (9.1%) 30 (90.9%) 
Stagec
I-II 11 6 (54.5%) 5 (45.5%) 0.007 
III-IV 29 3 (13.3%) 26 (89.7%) 
Debulkingd
OD 17 7 (41.2%) 10 (58.8%) 0.023 
SD 23 2 (8.7%) 21 (91.3%) 
aFisher’s exact test. bB, borderline; I, well differentiated; II, moderately
differentiated; III, poorly differentiated. cInternational Federation of
Gynaecology and Obstetrics (FIGO) staging system. dOD, optimal (0–1 cm);
SD, suboptimal (> 1 cm). 
Table 3 Putative post-translational modification sites in the novel SR-A1 gene 
Modification Residue Positiona
Thr 93, 264, 327, 330, 335, 420, 426, 428, 539, 619, 976, 994, 1044–48, 1050, 1057, 1083. 
O-glycosylation Ser 191, 194–96, 198, 200, 202–205, 207, 239, 259, 260, 261, 424, 498, 500, 536, 537, 620, 
670, 719, 804, 805, 814, 815, 817, 819, 1049, 1056, 1177. 
N-glycosylation Asn 165. 
cAMP-dependent protein kinase phosphorylation Ser 516, 523, 571, 584, 609, 751. 
Protein kinase C phosphorylation Ser 70, 166, 319, 341, 519, 552, 569, 582, 597, 624, 625, 640, 680, 762, 768, 792, 827. 
Thr 156, 488, 515, 923, 583, 590. 
Casein kinase 2 phosphorylation Ser 14, 102, 113, 266, 389, 453, 519, 548, 625, 649, 674, 689, 738, 747, 762, 965. 
Thr 87, 342, 357, 694. 
aThe residues are numbered according to the sequence shown in Figure 1. Molecular characterization of the SR-A1 gene 195
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SR-A1 expression in ovarian cancer 
Expression of the SR-A1 gene, at the mRNA level, was examined
in 40 ovarian tumours and 5 non-cancerous ovarian tissue speci-
mens, using RT-PCR. Actin was a positive control. Examples of
SR-A1 gene expression in normal ovarian tissue, and in tumours
with low or hight expression are shown in Figure 8. The distribu-
tions of SR-A1 qualitative expression status (high or low) between
subgroups of patients differing by tumour grade, disease stage and
success of debulking were examined by the Fisher’s exact test
(Table 4). SR-A1-high expression was found more frequently
in grade II–III, stage III–IV and suboptimal debulking patients (P
< 0.001, P = 0.007 and P = 0.023, respectively). Differences in
residual tumour size between the 2 SR-A1 status patients groups
were found to be statistically significant by the Mann–Whitney
test (P = 0.006). Median values of the residual tumour size were 0
and 3 for SR-A1-low and SR-A1-high tumours, respectively.
Although only 2 borderline tumours were available, it is worth
mentioning that the SR-A1 gene was not expressed in the above
tumours. Statistically significant association between SR-A1
status and patient age was not observed. 
DISCUSSION 
We have identified a human gene encoding for a new member of
the SR protein family. Using positional candidate gene analysis we
identified a gene spanning an area of 16.7 kb of genomic sequence
and we named it SR-A1, based on homologies with other members
of the SR protein family. EST analysis was used to delineate the
genomic organization of the gene and predict the putative mRNA
coding region. RT-PCR and sequencing were used verify the splice
junctions. The SR-A1 gene is formed of 11 coding exons and 10
intervening introns. Present at the 3¢-terminus of 2 ESTs was a
poly-A tail, while the 5¢-terminus of the mRNA coding region,
contained a well-conserved Kozak sequence (Kozak, 1991). The
new gene has 84% nucleotide identity to the rat A1 gene (rA1),
which is a member of the SR protein family. The human SR-A1
protein has highly-conserved SR and CTD-binding domains as
Figure 3 Alignment of the deduced amino acid sequence of SR-A1 with members of the SR gene family (rat A1, rat A9 and human SRrp129). Dashes
represent gaps to bring the sequences to better alignment. Conserved areas are highlighted in grey. The arrows mark start and end of the CTD-binding domain.
2 areas with polyglutamic acid stretches are marked with a solid line on top. The RD motif is marked with a solid double line on top. Maximum homology
between all 4 proteins is seen in the area of the CTD domain well as the Arg/Asp rich motif and 2 stretches of polyglutamic acid
areas, also found in rat A1. For these reasons, we consider our new
gene as the human homologue of rA1 (Yuryev et al, 1996). 
The SR protein family is very conserved, with molecular
weights of 20, 30, 40, 55 and 75 kDa, described in a number of
organisms (Zahler et al, 1993; Screaton et al, 1995). Human SR
proteins are encoded by nine distinct SR genes, and their sizes
range from 20 to 129 kDa. In addition, a number of alternatively
spliced isoforms have been reported (Screaton et al, 1995). A
group of high molecular weight SR proteins has also been identi-
fied, by their reactivity with the monoclonal antibody mAb104,
that recognizes an epitope of alternating phosphoserine and argi-
nine residues, and also by the fact that they can be readily precipi-
tated by Mg2+, a feature shared by all SR proteins (Blencowe et al,
1994). To our knowledge, no corresponding genes or cDNAs have
as yet been identified for these proteins. 
The predicted protein coding region of the SR-A1 gene is 3,939
bp, encoding for a 1312-amino acid polypeptide with a predicted
molecular weight of 139.3 kDa. This molecular weight is similar
to the one reported for the rA1 protein (Yuryev et al, 1996) and the
human SRrp129/CASP11 protein (Tanner et al, 1997). Further-
more, the SR-A1 protein has 78% and 22% identity with the rat A1
and human SRrp129/CASP11 protein, respectively. The SR
domains of the rat A1 are also present in the human SR-A1
protein. Thus, the SR-A1 protein appears to be a novel member of
the human SR family. 
Several lines of evidence suggest that the SR proteins play a
role in splicing (Zahler et al, 1993; Blencowe et al, 1994; Yuryev
et al, 1996), perhaps by linking the synthesis of mRNA with the
processing mechanism, specifically by regulating alternative
splicing (McKeown et al, 1987; Amrein et al, 1988; Goralski et al,
1989). Furthermore, an Arg/Asp (RD)-rich motif present in the
predicted SR-A1 protein was also found to be present in the 
RNA-binding proteins U1-70 K (Spritz et al, 1987), the RD 
RNA-binding protein (Surowy et al, 1990) and the 68 kDa human
pre-mRNA cleavage factor Im (Ruegsegger et al, 1998). The 
latter, has been implicated in processing of the 3¢ end and in the
regulation of the polyadenylation process (Takagaki et al, 1989,
1992). The same RD motif has also been identified in the rat 
SR proteins rA1, rA4 and rA8, but not the rA9 (Yuryev et al,
1996). 
Members of the SR family have been shown to exhibit overlap-
ping functions but can modulate alternative splicing of specific
pre-mRNAs (Wang et al, 1998). It has also been postulated that the
SR proteins participate in tumorigenesis by regulating alternative
splicing of several mRNAs such as the CD44 pre-mRNA splicing
in ovarian as well as mammary cancer (Cannistra et al, 1993;
Stickeler et al, 1999). 
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Figure 4 Dendrogram of the predicted phylogenetic tree for the known SR
proteins. Neighbour-joining/UPGMA method was used to align SR-A1 with
other members of the SR gene family. The tree aligned the SR-A1 protein in
one group with the rat A1 gene. Other SR proteins were aligned in different
groups 
Figure 5 Plot of hydrophobicity and hydrophilicity of SR-A1 protein. For discussion see text 
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The human SR-A1 gene is located on chromosome 19q13.3,
between the RRAS and IRF3 genes (Figure 1). The connection of
the RAS genes to human malignancy is well-known (Webb et al,
1998). IRF3 is a member of a growing family of transcription
factors. It is becoming increasingly apparent that IRF3 plays a
pivotal role in the cell’s response to viral infection. Phospho-
rylation and activation of IRF3 in response to stimuli other than
viral infection may result in transcription of genes, in addition to
the early inflammatory genes (Au et al, 1995; Lowther et al, 1999).
Activation of IRF3 by growth factors can lead to a negative feed-
back control of cell growth (Au et al, 1995). 
The human SR-A1 gene was shown to be expressed widely in
all normal tissues tested. However, the level of the SR-A1 tran-
scripts seem to vary between tissues. The highest level of SR-A1
transcripts was detected in the fetal brain and fetal liver and the
lowest in salivary gland, skin, uterus and ovary (Figure 6). 
Several ovarian tumour extracts were examined with respect to
SR-A1 expression. SR-A1 transcripts were shown to be differen-
tially regulated in ovarian tumors. The pattern of exprression
appears to correlate significantly with tumour grade, disease stage
and success of debulking (Table 4). The differential expression of
SR-A1 in ovarian tumours suggests that the SR-A1 protein may
participate in alternative splicing processes during progression of
ovarian tumours. Our data suggest that SR-A1 overexpression is
associated with clinically more aggressive ovarian tumours. 
In the mammary and prostate gland SR-A1 gene transcripts are
constitutively present at relatively high levels (Figure 6). The level
of the SR-A1 mRNA appears to increase in cell lines treated with
various steroid hormons (Figure 7). However, the mechanism of
this event needs further investigation. 
In conclusion, we cloned a gene that encodes for a novel SR-
protein, which appears to be the human homologue of the rat A1
gene cloned by Yuryev et al (1996). This gene is localized between
the 2 known genes; IRF3 and RRAS on chromosome 19q13.3. We
report that this gene is overexpressed in a subset of clinically more
aggressive ovarian cancers and speculate that SR-A1 may be
involved in the pathogenesis and/or progression of ovarian and
other cancers. 
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